{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:24:22Z","timestamp":1773678262909,"version":"3.50.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00398-4","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:37:53Z","timestamp":1762594673000},"page":"95-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-6935","authenticated-orcid":false,"given":"Marina E.","family":"Cazzaniga","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-7318","authenticated-orcid":false,"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-268X","authenticated-orcid":false,"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5278","authenticated-orcid":false,"given":"Piotr J.","family":"Wysocki","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-6917","authenticated-orcid":false,"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.","journal-title":"J Natl Cancer Inst"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsbmb.2015.05.005","volume":"153","author":"VS Wu","year":"2015","unstructured":"Wu VS, Kanaya N, Lo C, Mortimer J, Chen S. From bench to bedside: what do we know about hormone receptor-positive and human epidermal growth factor receptor\u00a02-positive breast cancer? J Steroid Biochem Mol Biol. 2015;153:45\u201353.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"398_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju152","volume":"106","author":"A Prat","year":"2014","unstructured":"Prat A, Carey LA, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106:dju152.","journal-title":"J Natl Cancer Inst"},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"398_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10\u00a0years. N Engl J Med. 2016;375:209\u201319.","journal-title":"N Engl J Med"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","volume":"20","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2019;20:88\u201399.","journal-title":"Lancet Oncol"},{"key":"398_CR8","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1200\/JCO.22.00577","volume":"41","author":"T Iwase","year":"2023","unstructured":"Iwase T, Saji S, Iijima K, et al. Postoperative adjuvant anastrozole for 10 or 5\u00a0years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase\u00a0III trial. J Clin Oncol. 2023;41:3329\u201338.","journal-title":"J Clin Oncol"},{"key":"398_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164190","volume":"15","author":"I Bekes","year":"2023","unstructured":"Bekes I, Huober J. Extended adjuvant endocrine therapy in early breast cancer patients-review and perspectives. Cancers (Basel). 2023;15:4190.","journal-title":"Cancers (Basel)"},{"key":"398_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11\u00a0years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389:1195\u2013205.","journal-title":"Lancet"},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"S310","DOI":"10.1016\/j.annonc.2024.08.176","volume":"35","author":"S Moon","year":"2024","unstructured":"Moon S, Bae SJ, Kook Y, et al. 233MO ovarian function suppression in HR-positive, HER2-positive breast cancer: an exploratory analysis from the HERA trial. Ann Oncol. 2024;35:S310.","journal-title":"Ann Oncol"},{"key":"398_CR12","unstructured":"Metzger O, Mandrekar S, DeMichele A, et al. AFT-38 PATINA: A randomized, open label, phase\u00a0III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive (HR+)\/HER2-positive metastatic breast cancer [abstract + oral presentation]. 47th San Antonio Breast Cancer Symposium (SABCS); 2024; San Antonio, Texas."},{"key":"398_CR13","doi-asserted-by":"crossref","unstructured":"Piccart M, Procter M, Fumagalli D, et al. Interim overall survival analysis of APHINITY (BIG 4\u201311): a randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [SABCS abstract]. Cancer Res. 2020; 80:GS1\u201304.","DOI":"10.1158\/1538-7445.SABCS19-GS1-04"},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328.","journal-title":"N Engl J Med"},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.22.02241","volume":"41","author":"MT van Mackelenbergh","year":"2023","unstructured":"van Mackelenbergh MT, Loibl S, Untch M, et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor\u00a02 therapy of human epidermal growth factor receptor\u00a02-positive early breast cancer. J Clin Oncol. 2023;41:2998\u20133008.","journal-title":"J Clin Oncol"},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.19.00443","volume":"37","author":"S Chumsri","year":"2019","unstructured":"Chumsri S, Li Z, Serie DJ, et al. Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (Alliance) and NRG Oncology\/NSABP B-31. J Clin Oncol. 2019;37:3425\u201335.","journal-title":"J Clin Oncol"},{"key":"398_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9:500\u201310.","journal-title":"JAMA Oncol"},{"key":"398_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41523-025-00737-8","volume":"11","author":"CD Cha","year":"2025","unstructured":"Cha CD, Kim KE, Kim J, et al. Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status. NPJ Breast Cancer. 2025;11:31.","journal-title":"NPJ Breast Cancer"},{"issue":"242\u201350","key":"398_CR19","volume":"25","author":"S Liu","year":"2025","unstructured":"Liu S, Du B, Zhou S, et al. Patterns of recurrence and survival outcomes of HER2-low expression in early-stage breast cancer. Clin Breast Cancer. 2025;25(242\u201350):e6.","journal-title":"Clin Breast Cancer"},{"key":"398_CR20","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.1038\/ncomms12222","volume":"7","author":"A Ferrari","year":"2016","unstructured":"Ferrari A, Vincent-Salomon A, Pivot X, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016;7:12222.","journal-title":"Nat Commun"},{"key":"398_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339\u201350.","journal-title":"Breast"},{"key":"398_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","volume":"23","author":"J O\u2019Shaughnessy","year":"2023","unstructured":"O\u2019Shaughnessy J, Gradishar W, O\u2019Regan R, Gadi V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer. 2023;23:350\u201362.","journal-title":"Clin Breast Cancer"},{"key":"398_CR23","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1158\/1078-0432.CCR-19-0560","volume":"25","author":"TG Steenbruggen","year":"2019","unstructured":"Steenbruggen TG, van Seijen M, Janssen LM, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by residual cancer burden, neoadjuvant response index, and neo-bioscore. Clin Cancer Res. 2019;25:4985\u201392.","journal-title":"Clin Cancer Res"},{"key":"398_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103880","volume":"181","author":"A Mittal","year":"2023","unstructured":"Mittal A, Tamimi F, Molto C, et al. Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: a meta-analysis. Crit Rev Oncol Hematol. 2023;181:103880.","journal-title":"Crit Rev Oncol Hematol"},{"key":"398_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/modpathol.2015.53","volume":"28","author":"F Peintinger","year":"2015","unstructured":"Peintinger F, Sinn B, Hatzis C, et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015;28:913\u201320.","journal-title":"Mod Pathol"},{"key":"398_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2021.05.018","volume":"153","author":"V Guarneri","year":"2021","unstructured":"Guarneri V, Dieci MV, Griguolo G, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-lob trial. Eur J Cancer. 2021;153:133\u201341.","journal-title":"Eur J Cancer"},{"key":"398_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23:149\u201360.","journal-title":"Lancet Oncol"},{"key":"398_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41571-019-0299-9","volume":"17","author":"K Goutsouliak","year":"2020","unstructured":"Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17:233\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase\u00a0II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27\u201335.","journal-title":"Eur J Cancer"},{"key":"398_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase\u00a02 randomised trial. Lancet Oncol. 2016;17:791\u2013800.","journal-title":"Lancet Oncol"},{"key":"398_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2021.01.053","volume":"148","author":"A Moreno-Aspitia","year":"2021","unstructured":"Moreno-Aspitia A, Holmes EM, Jackisch C, et al. Updated results from the international phase\u00a0III ALTTO trial (BIG 2\u201306\/Alliance N063D). Eur J Cancer. 2021;148:287\u201396.","journal-title":"Eur J Cancer"},{"key":"398_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-019-05284-y","volume":"177","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Campbell C, Gelber RD, et al. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2\u201306) randomized clinical trial. Breast Cancer Res Treat. 2019;177:103\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"398_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24\u00a0years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 2016;34:927\u201335.","journal-title":"J Clin Oncol"},{"key":"398_CR34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","volume":"187","author":"J O\u2019Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy J, Robert N, Annavarapu S, et al. Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study. Breast Cancer Res Treat. 2021;187:903\u201313.","journal-title":"Breast Cancer Res Treat"},{"key":"398_CR35","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.21873\/anticanres.14314","volume":"40","author":"M Okamoto","year":"2020","unstructured":"Okamoto M, Tajiri W, Ueo H, et al. Efficacy of adjuvant combination therapy with trastuzumab and chemotherapy in HER2-positive early breast cancer: a single institutional cohort study from clinical practice. Anticancer Res. 2020;40:3315\u201323.","journal-title":"Anticancer Res"},{"key":"398_CR36","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5\u00a0years. N Engl J Med. 2017;377:1836\u201346.","journal-title":"N Engl J Med"},{"key":"398_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.02.015","volume":"130","author":"G Werutsky","year":"2020","unstructured":"Werutsky G, Untch M, Hanusch C, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: a pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020;130:92\u2013101.","journal-title":"Eur J Cancer"},{"key":"398_CR38","doi-asserted-by":"crossref","unstructured":"Huszno J, Kolosza Z, Kwarciak JM, Zajusz A. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio breast cancer patients according to HER2 overexpression [SABCS abstract: P3-08-67]. Cancer Res. 2020; 80:P3-08-67.","DOI":"10.1158\/1538-7445.SABCS19-P3-08-67"},{"key":"398_CR39","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0960-9776(19)30122-5","volume":"44","author":"J Shiau","year":"2019","unstructured":"Shiau J, Fu OY, Wu CC, et al. Long-term follow-up of HER2-positive early breast cancer patients with adjuvant trastuzumab: the real-world result and unmet needs [SGBCC abstract: P021]. Breast. 2019;44:S22\u20133.","journal-title":"Breast"},{"key":"398_CR40","doi-asserted-by":"crossref","unstructured":"Rosario MH, Sahoo S. Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy [SABCS abstract: P3-08-63]. Cancer Res. 2020; 80:P3-08-63.","DOI":"10.1158\/1538-7445.SABCS19-P3-08-63"},{"key":"398_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40\u201350.","journal-title":"Lancet Oncol"},{"key":"398_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2019.05.014","volume":"118","author":"T Ochi","year":"2019","unstructured":"Ochi T, Bianchini G, Ando M, et al. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019;118:41\u20138.","journal-title":"Eur J Cancer"},{"key":"398_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/annonc\/mdz007","volume":"30","author":"MV Dieci","year":"2019","unstructured":"Dieci MV, Conte P, Bisagni G, et al. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol. 2019;30:418\u201323.","journal-title":"Ann Oncol"},{"key":"398_CR44","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.CCR-22-2829","volume":"29","author":"A Matikas","year":"2023","unstructured":"Matikas A, Johansson H, Gryback P, et al. Survival outcomes, digital TILs, and on-treatment PET\/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial. Clin Cancer Res. 2023;29:532\u201340.","journal-title":"Clin Cancer Res"},{"key":"398_CR45","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1016\/j.annonc.2020.08.351","volume":"31","author":"A Gasol Cudos","year":"2020","unstructured":"Gasol Cudos A, Morales S, Rodriguez Galindo A, et al. Pathologic response to neoadjuvant therapy in HER2 positive\/oestrogen receptor positive breast cancer patients [ESMO abstract: 230P]. Ann Oncol. 2020;31:S333.","journal-title":"Ann Oncol"},{"key":"398_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"L Gianni","year":"2018","unstructured":"Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase\u00a02 study. Lancet Oncol. 2018;19:249\u201356.","journal-title":"Lancet Oncol"},{"key":"398_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00377-8","volume":"8","author":"L Gianni","year":"2022","unstructured":"Gianni L, Colleoni M, Bisagni G, et al. Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. NPJ Breast Cancer. 2022;8:1.","journal-title":"NPJ Breast Cancer"},{"key":"398_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.breast.2022.07.012","volume":"65","author":"A Viansone","year":"2022","unstructured":"Viansone A, Pellegrino B, Omarini C, et al. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. Breast. 2022;65:145\u201350.","journal-title":"Breast"},{"key":"398_CR49","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816\u201337.","journal-title":"J Clin Oncol"},{"key":"398_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801","volume":"75","author":"A Prat","year":"2022","unstructured":"Prat A, Guarneri V, Pascual T, et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine. 2022;75:103801.","journal-title":"EBioMedicine"},{"key":"398_CR51","first-page":"1285","volume":"27","author":"N O\u2019Donovan","year":"2007","unstructured":"O\u2019Donovan N, Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res. 2007;27:1285\u201394.","journal-title":"Anticancer Res"},{"key":"398_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/bjc.2014.556","volume":"112","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Seo AN, Kim EJ, et al. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer. 2015;112:103\u201311.","journal-title":"Br J Cancer"},{"key":"398_CR53","volume":"7","author":"H Zeng","year":"2024","unstructured":"Zeng H, Wang W, Zhang L, Lin Z. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs. Cancer Drug Resist. 2024;7:14.","journal-title":"Cancer Drug Resist"},{"key":"398_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024;15:903.","journal-title":"Genes"},{"key":"398_CR55","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.3390\/molecules26237376","volume":"26","author":"MI El-Gamal","year":"2021","unstructured":"El-Gamal MI, Mewafi NH, Abdelmotteleb NE, et al. A review of HER4 (ErbB4) kinase, its impact on cancer, and its inhibitors. Molecules. 2021;26:7376.","journal-title":"Molecules"},{"key":"398_CR56","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1158\/1078-0432.CCR-18-2206","volume":"25","author":"S Chumsri","year":"2019","unstructured":"Chumsri S, Serie DJ, Li Z, et al. Effects of age and immune landscape on outcome in HER2-positive breast cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) trials. Clin Cancer Res. 2019;25:4422\u201330.","journal-title":"Clin Cancer Res"},{"key":"398_CR57","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-19-0463","volume":"25","author":"X He","year":"2019","unstructured":"He X, Ji J, Tian M, et al. Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer. Clin Cancer Res. 2019;25:7388\u201395.","journal-title":"Clin Cancer Res"},{"key":"398_CR58","doi-asserted-by":"publisher","first-page":"175883592110069","DOI":"10.1177\/17588359211006960","volume":"13","author":"F Ligorio","year":"2021","unstructured":"Ligorio F, Zambelli L, Bottiglieri A, et al. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Ther Adv Med Oncol. 2021;13:17588359211006960.","journal-title":"Ther Adv Med Oncol"},{"key":"398_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2025.101064","volume":"14","author":"ME Schmidt","year":"2025","unstructured":"Schmidt ME, Goldschmidt S, Kreutz C, et al. Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: the randomized controlled BENEFIT trial. J Sport Health Sci. 2025;14:101064.","journal-title":"J Sport Health Sci"},{"key":"398_CR60","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2021","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 2021;22:1139\u201350.","journal-title":"Lancet Oncol"},{"key":"398_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","volume":"179","author":"E de Azambuja","year":"2020","unstructured":"de Azambuja E, Ponde N, Procter M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020;179:161\u201371.","journal-title":"Breast Cancer Res Treat"},{"key":"398_CR62","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122\u201331.","journal-title":"N Engl J Med"},{"key":"398_CR63","unstructured":"European Medicines Agency. Perjeta (pertuzumab): EPAR - product information. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/perjeta. Accessed Dec 3, 2024."},{"key":"398_CR64","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1200\/JCO.23.02505","volume":"42","author":"S Loibl","year":"2024","unstructured":"Loibl S, Jassem J, Sonnenblick A, et al. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor\u00a02-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update. J Clin Oncol. 2024;42:3643\u201351.","journal-title":"J Clin Oncol"},{"key":"398_CR65","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6\u00a0years\u2019 follow-up. J Clin Oncol. 2021;39:1448\u201357.","journal-title":"J Clin Oncol"},{"key":"398_CR66","doi-asserted-by":"crossref","unstructured":"Loibl S, Piccart M, Clark E, et al. Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3\u00a0years\u2019 median follow-up [ESMO abstract: LBA1]. ESMO Open. 2025;10:105112.","DOI":"10.1016\/j.esmoop.2025.105112"},{"key":"398_CR67","unstructured":"European Medicines Agency. Kadcyla (trastuzumab emtansine): EPAR - product information. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kadcyla. Accessed Dec 4, 2024."},{"key":"398_CR68","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer Jr","year":"2025","unstructured":"Geyer CE Jr, Untch M, Huang CS, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392:249\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"398_CR69","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1159\/000518696","volume":"16","author":"M Balic","year":"2021","unstructured":"Balic M, Rinnerthaler G, Bartsch R. Position paper on the value of extended adjuvant therapy with neratinib for early HER2+\/HR+ breast cancer. Breast Care. 2021;16(6):664\u201376.","journal-title":"Breast Care"},{"key":"398_CR70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40487-021-00153-5","volume":"9","author":"M Untch","year":"2021","unstructured":"Untch M, Martin M, De Laurentiis M, Gligorov J. How to optimise extended adjuvant treatment with neratinib for patients with early HER2+ breast cancer. Oncol Ther. 2021;9:297\u2013309.","journal-title":"Oncol Ther"},{"key":"398_CR71","unstructured":"US Food and Drug Administration. Nerlynx\u00ae (neratinib) tablets, for oral use: prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208051s009lbl.pdf. Accessed Aug 26, 2024."},{"key":"398_CR72","unstructured":"European Medicines Agency. Nerlynx (neratinib): summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nerlynx-epar-product-information_en.pdf. Accessed Mar 24, 2025."},{"key":"398_CR73","unstructured":"Pierre Fabre. Puma Biotechnology and Pierre Fabre amend NERLYNX\u00ae license agreement to include Greater China. 2021. https:\/\/www.pierre-fabre.com\/se-se\/nyheder\/press-release-puma-biotechnology-and-pierre-fabre-amend-nerlynxr-license-agreement-to. Accessed Jun 10, 2025."},{"key":"398_CR74","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","volume":"21","author":"A Chan","year":"2021","unstructured":"Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase\u00a0III ExteNET trial. Clin Breast Cancer. 2021;21:80-91.e7.","journal-title":"Clin Breast Cancer"},{"key":"398_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2023.02.002","volume":"184","author":"FA Holmes","year":"2023","unstructured":"Holmes FA, Moy B, Delaloge S, et al. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Eur J Cancer. 2023;184:48\u201359.","journal-title":"Eur J Cancer"},{"key":"398_CR76","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2016;17:367\u201377.","journal-title":"Lancet Oncol"},{"key":"398_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","volume":"175","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Di Palma JA, Tripathy D, et al. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res Treat. 2019;175:5\u201315.","journal-title":"Breast Cancer Res Treat"},{"key":"398_CR78","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.breast.2022.12.003","volume":"67","author":"A Chan","year":"2023","unstructured":"Chan A, Ruiz-Borrego M, Marx G, et al. Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2023;67:94\u2013101.","journal-title":"Breast"},{"key":"398_CR79","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378:771\u201384.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"398_CR80","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health"},{"key":"398_CR81","unstructured":"World Health Organization. Adherence to long-term therapies: evidence for action. 2013. https:\/\/apps.who.int\/iris\/handle\/10665\/42682. Accessed Aug 26, 2024."},{"key":"398_CR82","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1471-2407-12-474","volume":"12","author":"AS Oberguggenberger","year":"2012","unstructured":"Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer. 2012;12:474.","journal-title":"BMC Cancer"},{"key":"398_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000533657","volume":"19","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Wrobel D, Zaiss M, et al. Neratinib as extended adjuvant treatment of HER2-positive\/HR-positive early breast cancer patients in Germany, Austria, and Switzerland: interim results of the prospective, observational ELEANOR study. Breast Care (Basel). 2024;19:1\u20139.","journal-title":"Breast Care (Basel)"},{"key":"398_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA550","volume":"40","author":"S Patel","year":"2022","unstructured":"Patel S, McWilliams D, Thompson J, Patel M, Daugherty FJ. Evaluation of booster injections in maintaining peak immunity in a phase\u00a0IIb study evaluating HER2\/neu peptide GP2 (GLSI-100) versus GM-CSF alone after adjuvant trastuzumab in women with HER2-positive breast cancer [ASCO abstract: LBA550]. J Clin Oncol. 2022;40:LBA550.","journal-title":"J Clin Oncol"},{"key":"398_CR85","doi-asserted-by":"crossref","unstructured":"Patel S, McWilliams D, Fischette CT, et al. Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase\u00a0IIb study evaluating the use of HER2\/neu peptide GP2 + GM-CSF vs. GMCSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer [ASCO abstract: 542]. J Clin Oncol. 2021;39:542.","DOI":"10.1200\/JCO.2021.39.15_suppl.542"},{"key":"398_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers16010087","volume":"16","author":"CL Fernandes","year":"2023","unstructured":"Fernandes CL, Silva DJ, Mesquita A. Novel HER-2 targeted therapies in breast cancer. Cancers (Basel). 2023;16:87. https:\/\/doi.org\/10.3390\/cancers16010087.","journal-title":"Cancers (Basel)"},{"key":"398_CR87","doi-asserted-by":"publisher","first-page":"1136380","DOI":"10.3389\/fonc.2023.1136380","volume":"13","author":"X Liu","year":"2023","unstructured":"Liu X, Zhang P, Li C, et al. Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China. Front Oncol. 2023;13:1136380.","journal-title":"Front Oncol"},{"key":"398_CR88","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","volume":"26","author":"S Escriv\u00e1-de-Romani","year":"2025","unstructured":"Escriv\u00e1-de-Romani S, Cejalvo JM, Alba E, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase\u00a02a study. Lancet Oncol. 2025;26:745\u201358.","journal-title":"Lancet Oncol"},{"key":"398_CR89","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1016\/j.annonc.2023.09.445","volume":"34","author":"L Ma","year":"2023","unstructured":"Ma L, Yang B, Zhang M, et al. KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): a single-arm, multicenter, phase\u00a0II study [ESMO abstract: 247P]. Ann Oncol. 2023;34:S282.","journal-title":"Ann Oncol"},{"key":"398_CR90","doi-asserted-by":"publisher","first-page":"S358","DOI":"10.1016\/j.annonc.2023.09.595","volume":"34","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Wang J, Ouyang Q, et al. Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent\/metastatic breast cancer [ESMO abstract: 418P]. Ann Oncol. 2023;34:S358.","journal-title":"Ann Oncol"},{"key":"398_CR91","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1016\/j.annonc.2022.03.195","volume":"33","author":"YH Park","year":"2022","unstructured":"Park YH, Jung KH, Sohn J, et al. Poziotinib for HER2-positive metastatic breast cancer (MBC): final clinical efficacy and safety results for long-term follow-up of the phase\u00a0II NOV120101-203 trial [ESMO abstract: 176P]. Ann Oncol. 2022;33:S207\u20138.","journal-title":"Ann Oncol"},{"key":"398_CR92","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1002\/ijc.31651","volume":"143","author":"YH Park","year":"2018","unstructured":"Park YH, Lee KH, Sohn JH, et al. A phase\u00a0II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int J Cancer. 2018;143:3240\u20137.","journal-title":"Int J Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00398-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:04:33Z","timestamp":1773673473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00398-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marina E. Cazzaniga has received grants or research support from Eli Lilly and EISAI; received honoraria or consultation fees from MSD, Pierre Fabre, Novartis, Roche, Lilly, and Exact Science; and participated in a company sponsored speaker\u2019s bureau for Novartis, Pfizer, and Eli Lilly. Luis Costa has received grants or research support from Eli Lilly, Roche, Amgen, and MSD; has received honoraria or consultation fees from Servier, MSD, AstraZeneca, and Pierre Fabre; and participated in a company sponsored speaker\u2019s bureau for Novartis, Pfizer, Eli Lilly, MSD, and AstraZeneca. Gilles Freyer and Joseph Gligorov have received honoraria and\/or consulting fees from Pierre Fabre. Henrik Lindman has received lecture honoraria from Novartis, AstraZeneca, Daiichi Sankyo, Pierre Fabre, and MSD; and received consultation fees from Lilly, MSD, Daiichi Sankyo, Pierre Fabre, Seagen, AstraZeneca, Gilead, and medac Pharma. Piotr J. Wysocki has acted in an advisory role for AstraZeneca, Astellas, Eli Lilly, Gilead, Immunicom, Janssen, MSD, Novartis, Pfizer, Pierre-Fabre, and Roche; received lecture honoraria from AstraZeneca, BMS, and MSD; and received research support from Immunicom. Rupert Bartsch has acted in an advisory role for AstraZeneca, Daiichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre Fabre, Puma, Roche, Seagen, and Stemline; has received lecture honoraria from AstraZeneca, BMS, Daichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, and Stemline; and received research support from Daiichi, MSD, Novartis, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}